Adicet Bio (FRA:1IJ) Piotroski F-Score: 1 (As of Jun. 29, 2026) — 67% Below Median


FRA:1IJ Adicet Bio Inc FRA:1IJ
31 GF Score
Price €7.05
! 3 Warning Signs
View Full Analysis

What is Adicet Bio Piotroski F-Score?

Adicet Bio FRA:1IJ -5.04% 31 Piotroski F-Score is 1 as of Jun. 29, 2026, which is 67% below its 10-year median of 3.00. GuruFocus rates FRA:1IJ with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 1,339 Biotechnology companies, Adicet Bio ranks worse than 92.23% on this metric.

Warning Sign:

Piotroski F-Score of 1 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Adicet Bio has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Adicet Bio's Piotroski F-Score or its related term are showing as below:

FRA:1IJ' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 5
Current: 1

During the past 8 years, the highest Piotroski F-Score of Adicet Bio was 5. The lowest was 1. And the median was 3.

Adicet Bio  (FRA:1IJ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Adicet Bio Piotroski F-Score Related Terms


Adicet Bio Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Adicet Bio's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adicet Bio Piotroski F-Score Chart

Adicet Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial 4.00 4.00 1.00 3.00 2.00

Adicet Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 2.00 2.00 1.00

FRA:1IJ vs EDSA, GOSS, HRTX: Piotroski F-Score Comparison

For the Biotechnology subindustry, Adicet Bio's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adicet Bio Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adicet Bio's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Adicet Bio's Piotroski F-Score falls into.


FRA:1IJ
31GF Score
Adicet Bio Inc FRA:1IJ
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -27.065 + -22.881 + -26.061 + -17.511 = €-93.52 Mil.
Cash Flow from Operations was -23.091 + -19.006 + -17.856 + -18.589 = €-78.54 Mil.
Revenue was 0 + 0 + 0 + 0 = €0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = €0.00 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(176.926 + 141.297 + 119.688 + 164.271 + 146.515) / 5 = €149.7394 Mil.
Total Assets at the begining of this year (Mar25) was €176.93 Mil.
Long-Term Debt & Capital Lease Obligation was €9.53 Mil.
Total Current Assets was €121.16 Mil.
Total Current Liabilities was €15.83 Mil.
Net Income was -27.778 + -27.461 + -27.434 + -26.098 = €-108.77 Mil.

Revenue was 0 + 0 + 0 + 0 = €0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = €0.00 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(269.647 + 249.754 + 221.612 + 210.309 + 176.926) / 5 = €225.6496 Mil.
Total Assets at the begining of last year (Mar24) was €269.65 Mil.
Long-Term Debt & Capital Lease Obligation was €12.27 Mil.
Total Current Assets was €142.05 Mil.
Total Current Liabilities was €15.21 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Adicet Bio's current Net Income (TTM) was -93.52. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Adicet Bio's current Cash Flow from Operations (TTM) was -78.54. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-93.518/176.926
=-0.52857127

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-108.771/269.647
=-0.40338294

Adicet Bio's return on assets of this year was -0.52857127. Adicet Bio's return on assets of last year was -0.40338294. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Adicet Bio's current Net Income (TTM) was -93.52. Adicet Bio's current Cash Flow from Operations (TTM) was -78.54. ==> -78.54 > -93.52 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=9.531/149.7394
=0.06365058

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=12.267/225.6496
=0.05436305

Adicet Bio's gearing of this year was 0.06365058. Adicet Bio's gearing of last year was 0.05436305. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=121.161/15.828
=7.65485216

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=142.046/15.213
=9.33714586

Adicet Bio's current ratio of this year was 7.65485216. Adicet Bio's current ratio of last year was 9.33714586. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Adicet Bio's number of shares in issue this year was 10.745. Adicet Bio's number of shares in issue last year was 5.692. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Adicet Bio's gross margin of this year was . Adicet Bio's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=0/176.926
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=0/269.647
=0

Adicet Bio's asset turnover of this year was 0. Adicet Bio's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+0+0
=1

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Adicet Bio has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 1 mean?
Adicet Bio (FRA:1IJ) has a Piotroski F-Score of 1 as of Jun. 29, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Adicet Bio and its competitors. This is 67% below median its historical median of 3.00. Over the past decade, Adicet Bio's Piotroski F-Score has ranged from 1.00 to 5.00. According to the industry distribution chart, Adicet Bio ranks #1235 out of 1339 companies in the Biotechnology industry, placing it in the top 92.2%.
Is Adicet Bio's Piotroski F-Score too high?
Adicet Bio's current Piotroski F-Score of 1 is 67% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 5.00. The Biotechnology industry median Piotroski F-Score is 3.00. Adicet Bio's value of 1 is 66.7% below this industry median. Based on the distribution chart, Adicet Bio ranks #1235 out of 1339 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Adicet Bio has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's Piotroski F-Score compare to EDSA and GOSS?
According to the Biotechnology industry distribution chart, Adicet Bio ranks #1235 out of 1339 companies for Piotroski F-Score. This places Adicet Bio in the lower half of its industry. The industry median Piotroski F-Score is 3.00. Adicet Bio's value of 1 is 66.7% below this benchmark. Historically, Adicet Bio's own Piotroski F-Score has ranged from 1.00 to 5.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, Adicet Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,339 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adicet Bio's current Piotroski F-Score of 1 is 66.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Adicet Bio and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adicet Bio's current Piotroski F-Score is 1, which is 67% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Adicet Bio (FRA:1IJ) has a current Piotroski F-Score of 1. The current Piotroski F-Score is 1, which is 67% below median its 10-year median of 3.00 and 66.7% below the Biotechnology industry median of 3.00. Adicet Bio's overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Adicet Bio (FRA:1IJ), the current Piotroski F-Score is 1 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adicet Bio Business Description

Other Exchanges ACET:USA0HX7:UK
Address 131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
31GF Score

Get the complete analysis for FRA:1IJ

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.05
Price